The Trump administration's recent 'most favored nation' agreements with 16 major pharmaceutical companies, aimed at aligning US drug prices with those in other developed nations, have not prevented widespread list price hikes in early 2026. According to analysis by drug pricing research firm 46brooklyn, all 16 companies raised prices on a total of 872 brand-name drugs within the first two weeks of January, affecting treatments for cancer, heart failure, Type 2 diabetes, and even some COVID-19 vaccines. The median increase stood at 4%, consistent with the previous year, despite the high-profile deals announced since September 2025.[2]

These deals, often referred to as most favored nation pacts, were designed to lower costs for American consumers by pressuring other wealthy countries to pay more for innovative drugs while securing discounts for US patients. However, pharmaceutical list prices serve as the baseline for negotiations with insurers and pharmacy benefit managers (PBMs), influencing formulary coverage and out-of-pocket costs. White House spokesperson Kush Desai emphasized that the deals focus on specific discounts for state Medicaid programs and cash-paying patients, dismissing list price fluctuations as irrelevant to the agreements' intent.[2]

Pfizer, the first to ink a deal in September, implemented a 15% hike on its COVID-19 shot and raised prices on 72 products overall. The company justified these moves as necessary to fund new medicine development and offset expenses, noting that net prices paid by insurers, after rebates, have actually declined. Merck followed suit, increasing prices on 18 drugs including HIV treatment Isentress and insomnia drug Belsomra, citing clinical value and commitments to fairer global pricing under confidential terms.[2]

Amid the increases, a smaller subset of drugs saw reductions, including 18 major price cuts. Notably, four drugs from the initial Medicare negotiations under the Inflation Reduction Act (IRA)—Fiasp insulin from Novo Nordisk (75% cut), AstraZeneca's Farxiga, Boehringer Ingelheim's Jardiance, and Bristol Myers Squibb's Eliquis—experienced drops of 37% to 44%. Analysts like Antonio Ciaccia of 46brooklyn attribute these to Medicare's leverage, describing it as the 'straw that broke the camel's back' for manufacturers facing multi-faceted pressures.[2]

The broader context involves ongoing regulatory shifts. The Trump administration is pushing Congress to codify these deals through the Great Healthcare Plan, as stated by CMS leader Dr. Mehmet Oz. Meanwhile, IRA-mandated Medicare negotiations continue, with the first 10 drugs seeing 38-79% reductions effective in 2026, though their commercial market impact varies. Experts like Dr. Ben Rome from Brigham and Women's Hospital caution that these deals have limited scope, not broadly affecting most products or private insurance plans.[2]

For B2B pharmaceutical stakeholders, including CROs, CMOs, and supply chain managers, these developments underscore pricing volatility's impact on procurement, contract negotiations, and compliance strategies. Companies must navigate confidential deal terms, IRA litigation in the Supreme Court, and potential tariff-linked investments in US manufacturing, as seen in parallel agreements with AstraZeneca and Pfizer committing billions to domestic R&D and production sites.[2][6]

Strategic implications extend to outsourcing and manufacturing. Firms like Sanofi, reporting strong 2025 pharma sales growth from launches like Ayvakit and ALTUVIIIO, anticipate high single-digit sales increases in 2026 alongside EPS growth and a €1 billion share buyback. Such financial maneuvers signal resilience but highlight the need for executives to monitor how pricing deals intersect with global supply chains and innovation investments.[5]

Regulatory teams should note CMS's expansion of IRA negotiations to 15 high-spend drugs, including GSK's Anoro Ellipta and AbbVie's Botox, targeting $27 billion in Medicare spending. This includes first-time Part B drugs, with prices effective in 2028, pressuring manufacturers to adapt contract services and validation processes.[4]

In summary, while deals promise targeted relief, persistent list price dynamics challenge pharma operations, urging R&D heads and procurement professionals to prioritize flexible supply chain solutions and compliance readiness amid evolving US policies.[2]